Related Experiment Video
Updated: Oct 14, 2025

04:42
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
616
Dopamine D2 receptor regulates cortical synaptic pruning in rodents.
Ya-Qiang Zhang1, Wei-Peng Lin1,2, Li-Ping Huang1
1Key Laboratory of Brain Functional Genomics, Ministry of Education and Shanghai, School of Life Science, East China Normal University, 200062, Shanghai, China.
Nature Communications
|November 9, 2021
Summary
Dopamine D2 receptor (Drd2) regulates adolescent synaptic pruning in the brain. Deficits in this process are linked to anxiety-like behaviors and altered brain function.
Area of Science:
- Neuroscience
- Molecular Biology
- Developmental Biology
Background:
- Synaptic pruning during adolescence is crucial for neurodevelopment and plasticity.
- Abnormal synaptic pruning is implicated in disorders like schizophrenia, autism, and anxiety.
- Dopamine D2 receptor (Drd2) is a key target for neuropsychiatric treatments.
Purpose of the Study:
- To investigate the role of Dopamine D2 receptor (Drd2) in regulating synaptic pruning.
- To explore the cellular mechanisms underlying Drd2-mediated synaptic pruning.
- To determine the long-term consequences of aberrant Drd2 function on brain activity and behavior.
Main Methods:
- Generation of self-reporting Drd2 heterozygous (SR-Drd2+/-) rats.
- Time course studies on the developing anterior cingulate cortex (ACC).
- Analysis of synaptic plasticity, including long-term depression (LTD), and mTOR signaling pathways.
Main Results:
- Drd2 plays a critical role in regulating synaptic pruning, not synapse formation.
- Drd2 influences synaptic plasticity, specifically LTD, which shares mechanisms with pruning.
- Drd2 regulates pruning through cell-autonomous mechanisms involving mTOR signaling activation.
Conclusions:
- Dopamine D2 receptor is essential for proper cortical synaptic pruning during adolescence.
- Adolescent deficits in Drd2-mediated pruning lead to adult hyper-glutamatergic function and anxiety.
- These findings highlight Drd2 as a potential therapeutic target for related neuropsychiatric disorders.

